Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Optimizing the treatment of hypothyroidism

Daily levothyroxine (LT4) is the standard of care for the treatment of hypothyroidism; however, a small number of patients experience residual symptoms of hypothyroidism. Guidelines indicate that a trial with LT4 and liothyronine (LT3) could be attempted once other conditions have been addressed or excluded. Even so, currently, treatment of hypothyroidism can still be suboptimal.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Bianco, A. C. Rethinking Hypothyroidism (Univ. Chicago Press, 2022).

  2. Penna, G. C., Bensenor, I. M., Bianco, A. C. & Ettleson, M. D. Thyroid hormone homeostasis in levothyroxine-treated patients: findings from ELSA-Brasil. J. Clin. Endocrinol. Metab. (2024).

    Article  PubMed  Google Scholar 

  3. Idrees, T., Palmer, S., Maciel, R. M. B. & Bianco, A. C. Liothyronine and desiccated thyroid extract in the treatment of hypothyroidism. Thyroid 30, 1399–1413 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Jonklaas, J. et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid 31, 156–182 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Shakir, M. K. M. et al. Comparative effectiveness of levothyroxine, desiccated thyroid extract, and levothyroxine+liothyronine in hypothyroidism. J. Clin. Endocrinol. Metab. 106, e4400–e4413 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Dumitrescu, A. M. et al. Extended absorption of liothyronine from poly-zinc-liothyronine: results from a phase 1, double-blind, randomized, and controlled study in humans. Thyroid 32, 196–205 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ettleson, M. D. et al. Demographic, healthcare access, and dietary factors associated with thyroid hormone treatments for hypothyroidism. J. Clin. Endocrinol. Metab. 108, e1614–e1623 (2023).

    Article  PubMed  Google Scholar 

  8. Taylor, P. N. et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern. Med. 174, 32–39 (2014).

    Article  CAS  PubMed  Google Scholar 

  9. Ahluwalia, R. et al. Use of liothyronine (T3) in hypothyroidism: joint British Thyroid Association/Society for Endocrinology consensus statement. Clin. Endocrinol. 99, 206–216 (2023).

    Article  CAS  Google Scholar 

  10. Taylor, P. N. et al. Liothyronine cost and prescriptions in England. Lancet Diabetes Endocrinol. 7, 11–12 (2019).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Antonio C. Bianco.

Ethics declarations

Competing interests

A.C.B. is a consultant for AbbVie, Acella, Synthonics. P.N.T. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bianco, A.C., Taylor, P.N. Optimizing the treatment of hypothyroidism. Nat Rev Endocrinol 20, 379–380 (2024).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing